Tobira Therapeutics, Inc. Common Stock
TBRA
TBRA was delisted on the 31st of October, 2016.
68 hedge funds and large institutions have $505M invested in Tobira Therapeutics, Inc. Common Stock in 2016 Q3 according to their latest regulatory filings, with 36 funds opening new positions, 20 increasing their positions, 5 reducing their positions, and 13 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 5
244% more capital invested
Capital invested by funds: $147M → $505M (+$358M)
177% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 13
51% more funds holding
Funds holding: 45 → 68 (+23)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
72% less call options, than puts
Call options by funds: $1.18M | Put options by funds: $4.17M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$41.3M |
| 2 |
PC
Paulson & Co
New York
|
+$11.9M |
| 3 |
GL
Governors Lane
New York
|
+$10.3M |
| 4 |
BG
Baupost Group
Boston,
Massachusetts
|
+$1.79M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.78M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$25.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$16.3M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$9.53M |
| 4 |
A
Abingworth
London,
United Kingdom
|
-$7.38M |
| 5 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
-$5.88M |
TBRA Hedge Fund Activity: Q3 2016 in Review
68 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Tobira Therapeutics, Inc. Common Stock (TBRA) for Q3 2016, worth a combined $505M — up 244% from $147M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new TBRA positions and 13 closed out — a net gain of 23 holders — while 20 added to existing stakes and 5 trimmed.
The largest buyer was Pentwater Capital Management, opening a new position worth an estimated $41.3M. The largest seller was Novo Holdings A/S, exiting entirely with an estimated $25.5M sold.
- 68 institutional investors held Tobira Therapeutics, Inc. Common Stock (TBRA) as of Q3 2016, up from 45 in Q2 2016.
- Funds reported $505M of Tobira Therapeutics, Inc. Common Stock stock for Q3 2016, up 244% quarter-over-quarter.
- 36 funds opened new Tobira Therapeutics, Inc. Common Stock positions in Q3 2016 and 13 closed out, a net change of +23 holders.
- The largest Tobira Therapeutics, Inc. Common Stock buyer in Q3 2016 was Pentwater Capital Management, an estimated $41.3M added.
- The largest Tobira Therapeutics, Inc. Common Stock seller in Q3 2016 was Novo Holdings A/S, an estimated $25.5M sold.
Based on aggregated 13F filings for Q3 2016.